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Abstract
Agents that antagonize the action of GABA on ionotropic receptors are widely used to 
probe the function of this neurotransmitter. Three such agents are in common use: bicu-
culline, gabazine, and picrotoxinin. These three agents produce convulsions on systemic 
administration but act in significantly different ways. Bicuculline is a competitive antago-
nist of GABA
A
 receptors. Gabazine is also a competitive antagonist of GABA
A
 receptors, 
interacting with different residues on the receptors. Picrotoxinin is a noncompetitive 
antagonist acting on the chloride channel of GABA
A
 and several other ionotropic CYS-
loop receptors including glycine, GABAC, and 5-HT3 receptors. Many other structurally diverse agents are now known to act as GABA receptor antagonists, providing oppor-
tunities for the discovery of agents with selectivity for the myriad of ionotropic GABA 
receptors. TPMPA is a selective antagonist for GABAC receptors, which are insensitive to bicuculline. Like TPMPA, many antagonists of ionotropic GABA receptors are not con-
vulsants, indicating that there is still much to be learnt about GABA function in the brain 
from the study of such agents and their possible therapeutic uses. The most recently 
discovered GABA
A
 receptor nonconvulsive antagonist is S44819, which is subtype selec-
tive for α5-containing receptors, and is arousing much interest in relation to cognition.
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1. Introduction
“Advantages of an Antagonist” headed the Nature editorial in 1970 on the paper reporting the 
antagonist action of the convulsant alkaloid bicuculline on receptors for the neurotransmit-
ter GABA in the cat spinal cord [1, 2]. The editorial predicted “With this tool it should now 
be possible to map fairly rapidly the distribution of GABA-inhibitory synapses in the CNS, 
© 2018 The Author(s). Licensee InTech. This chapter is distributed under the terms of the Creative Commons
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and to determine whether they are as numerous and widely distributed as the relatively high 
GABA content of the tissue would suggest.” Indeed, interest in GABA antagonists contin-
ues today, with more than 120 publications per year containing the terms “bicuculline” and 
“GABA” since 1970 [3]. GABA-inhibitory synapses are widely distributed in the CNS with 
GABA being released by up to 40% of neurons in many brain regions [4]. Specific GABA 
receptor antagonists have been described as “essential tools of physiological and pharmaco-
logical elucidation of the different types of GABA receptor inhibition” [5].
GABA receptors can be divided into two major types based on their mechanism of action dat-
ing from the studies by David Hill and Norman Bowery in 1981 on the binding of the GABA 
analog baclofen to rat brain membranes [6]. They described a receptor that “differs from the 
classical GABA site as it is unaffected by recognized GABA antagonists such as bicuculline.” 
They went on to state “We propose to designate the classical site as the GABA
A
 and the novel 
site as the GABA
B
 receptor.” We now know that GABA
A
 receptors are ionotropic receptors 
and that GABA
B
 receptors are metabotropic. This perspective on GABA receptor antagonists 
is limited to mammalian ionotropic receptors.
Ionotropic GABA receptors are ligand-gated ion channels, where binding of GABA neces-
sitates a change in conformation, which leads to opening of the ion channel. The ion channel 
is permeable to chloride, and increased conductance of this anion stabilizes the membrane 
potential, thereby reducing excitatory depolarization of the postsynaptic membrane. On the 
other hand, metabotropic GABA receptors are G-protein-coupled receptors, where GABA 
binding activates a variety of second messengers that lead to closing of cation channels to 
prevent sodium and calcium entry and opening of potassium channels to permit potassium 
efflux. The net effect is a reduction in excitability of the pre- or postsynaptic cell.
Ionotropic GABA receptors are part of the CYS-loop group of receptors that include glycine 
and 5-HT
3
 receptors. Ionotropic GABA receptors may be divided into two classes based on 
their sensitivity to antagonists. GABA
A
 receptors may be antagonized selectively by bicucul-
line, while GABAC receptors are antagonized selectively by TPMPA ((1,2,5,6-tetrahydropyri-din-4-yl)methylphosphinic acid) and are insensitive to bicuculline [7]. It turns out that these 
two classes differ in several other respects. While GABAC receptors are relatively simple homo-
meric pentameric receptors, GABA
A
 receptors are complex heteromeric pentameric receptors 
consisting of a variety of protein subunits, resulting in different possible combinations and 
thus a myriad of receptor subtypes. The structural complexity of the GABA
A
 receptors further 
supports a range of allosteric binding sites which are binding targets for endogenous and 




 subunits along with a γ2L subunit permit high-affinity benzodiazepine binding [8]. Barbiturates are known to bind to an allosteric site on all GABA
A
 receptor subtypes [9]. As 
another example, receptors containing δ subunits are targets for endogenous neurosteroids 
and ethanol [10–12]. Development of subtype-selective agonists, antagonists, and modulators 
of the ionotropic GABA receptors is imperative to the provision of valuable experimental tools 
for elucidation of the distribution and various functions of these GABA
A
 receptor subtypes.
Antagonism of ionotropic GABA receptors may result from three distinct mechanisms: com-
petitive antagonism where the binding site for the drug may overlap with the GABA-binding 
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site, i.e., the orthosteric site; negative allosteric modulation where the drug binds to a site dis-
tinct from the orthosteric site to reduce the affinity of the agonist; and noncompetitive antago-
nism where the drug binds to a site on the chloride channel to reduce chloride permeability 
or channel opening by GABA [13]. In this perspective, we consider examples of all three types 
of antagonism of the ionotropic GABA receptors.
2. Picrotoxin, a channel blocker of ionotropic GABA receptors
The first reported GABA receptor antagonist was picrotoxin, a convulsant plant product, a 
combination of the Greek words “picros” (bitter) and “toxicon” (poison). It is a 50:50 mixture 
of picrotoxinin (Figure 1) and picrotin with picrotoxinin being the more active component as 
a GABA receptor antagonist. Early reports showed that picrotoxin antagonized the action of 
GABA at invertebrate inhibitory synapses and that it reduced presynaptic inhibition in the spi-
nal cord [14]. In 1968, Davidoff and Aprison showed that picrotoxin antagonized the inhibitory 
Figure 1. GABA
A
 receptor antagonists that are convulsants.
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action of glycine on spinal neurones [15]. Curtis et al. [16] reported antagonist action against 
both glycine and GABA, but the results were inconsistent due to the lack of ionization using 
the microiontophoresis method of drug administration.
These technical difficulties were eventually overcome using recombinant receptors with bath 
application of picrotoxin showing it to be a mixed/noncompetitive GABA
A
 receptor antagonist 
[17]. But picrotoxin was also shown to be an antagonist of other CYS-loop receptors, including 
glycine, GABAC, and 5-HT3 receptors [18]. Thus, the utility of picrotoxin (and also picrotoxinin) as an experimental tool is mitigated by its lack of selectivity for GABA
A
 receptors. It also has no 
therapeutic potential owing to its potent convulsant effects.
Many terpenoids related to picrotoxinin are convulsants acting on ionotropic receptors for 
GABA and glycine [19]. Of particular interest is tutin that occurs in the berries and flowers of 
the indigenous New Zealand tutu plant, Coriaria arborea, and has been credited with convuls-
ing a circus elephant that consumed the berries [20]. Toxic honey was also produced from 
bees that collected nectar from the flowers.
3. Bicuculline, a competitive antagonist of GABA
A
 receptors
The discovery of bicuculline as a selective antagonist of what became known as GABA
A
 recep-
tors arose out of a systematic study of convulsant alkaloids [3]. It was well known that the 
most widely understood convulsant alkaloid, strychnine, antagonized the inhibitory action 
of glycine without influencing the inhibitory action of GABA [21]. Indeed, most convulsant 
alkaloids turned out to be glycine receptor antagonists with the important exception of bicu-
culline (Figure 1), an alkaloid from Dicentra cucullaria [22].
While bicuculline is selective for GABA
A
 receptors, having little effect on GABA
B
, GABAC, glycine, and 5-HT
3
 receptors, its action is largely independent of GABA
A
 subunit composition 
[17, 23]. Selectivity for GABA
A
 receptors makes bicuculline a powerful experimental tool but 
without any therapeutic potential owing to the nonselective nature of binding to all GABA
A
 
receptor subtypes, causing profound convulsive effects. Bicuculline binds at the orthosteric 
site to stabilize the receptor in a closed state. It is three times the size of GABA and thus is able 
to bind to sites on the receptor that GABA cannot reach [3]. Bicuculline acts as a competitive 
antagonist in which it competitively inhibits GABA agonist binding to GABA
A
 receptors, and 
GABA competitively inhibits bicuculline binding [24]. Single channel studies show that by 
competing with GABA for its binding site, bicuculline acts to reduce both chloride channel 
open time and opening frequency [25].
At physiological pH, bicuculline is slowly converted to bicucine, a much less active convul-
sant [26]. This transformation is slowly reversed at acidic pH. Thus, bicuculline solutions 
should always be freshly prepared in order to preserve maximum convulsant potency. 
Quaternary salts of bicuculline, such as bicuculline methiodide (“N-methyl bicuculline”) or 
methochloride, are much more stable than bicuculline, are more water soluble, and are of 
similar potency as GABA receptor antagonists, but they do not cross the blood-brain barrier 
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on systemic administration [27, 28]. The quaternary salts differ in their pharmacology to bicu-
culline itself in that they are much less selective. It is not always clear in publications whether 
the investigators use bicuculline or a quaternary salt [3]. The quaternary salts have significant 
actions on nicotinic receptors, calcium-activated potassium channels, and acetylcholinester-
ase [29–31]. Thus, while ensuring chemical stability of bicuculline, the quaternary salts may 
be less effective tools owing to their reduced binding specificity for GABA
A
 receptors. Subject 
to these considerations, bicuculline and its quaternary salts continue to be used extensively as 
GABA
A
 receptor antagonists in experimentation.
Extensive structure-activity studies have been carried out on bicuculline with little improvement 
on potency, selectivity, or stability [3]. Investigations of bicuculline analogs devoid of the phenyl 
ring fused to the lactone moiety have yielded positive allosteric modulators. These analogs do not 
bind to the orthosteric binding site on GABA
A
 receptors. Instead, they bind to the high-affinity 
benzodiazepine site on GABA
A
 receptor subtypes containing subunit combinations described 
above and show subtype selectivity that differs from that shown by benzodiazepines [32].
Bicuculline has been shown to improve special memory in the rat hippocampus [33].
4. Gabazine, a competitive antagonist of GABA
A
 receptors
Gabazine (also known as SR 95531, Figure 1) resulted from a study of arylaminopyridazine 
analogs of GABA. It was found to be a relatively specific, potent, and competitive antagonist 
of GABA
A
 receptors [34]. Although both are functionally competitive inhibitors, gabazine and 
bicuculline also interact with other residues on GABA
A
 receptors [35, 36]. Neither gabazine 
nor bicuculline compete for the binding at the barbiturate or neurosteroid binding sites on 
GABA
A
 receptors. It is suggested that both antagonists act “as allosteric inhibitors of channel 
opening for the GABA
A
 receptor after binding to the GABA-binding site” [36]. Gabazine has 
little activity at GABAC receptors [37]. At binary β3δ recombinant GABAA receptors, gabazine antagonized GABA currents, whereas bicuculline activated these receptors [38]. Thus, while 
functioning as competitive antagonists for GABA
A
 receptors, gabazine and bicuculline clearly 
interact with different residues on GABA
A
 receptors.
Structural analogs of gabazine have identified more potent agents [39]. Gabazine analogs 
incorporating photoactive groups, such as GZ-B1 (Figure 1), have been developed as photo-
activated antagonists of GABA
A
 receptors [40]. These antagonists provide dynamic tools for 
visualizing GABA
A
 receptors, permitting a novel means of investigating receptor location, 
function, and trafficking [40].




GABAC receptors, also known as GABA-ρ and GABAA-ρ receptors, have distinctive distribution 
and pharmacological properties to GABA
A
 receptors, making them particularly interesting [41]. 
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They are CYS-loop ligand-gated ion channels with a similar pentameric structure to GABA
A
 
receptors but are not so widely distributed. They are homomeric rather than heteromeric and 
therefore much simpler receptors. These properties make them important drug targets [42].
TPMPA ((1,2,5,6-Tetrahydropyridin-4-yl)methylphosphinic acid, Figure 2) was the first selec-
tive GABAC receptor antagonist to be synthesized [43, 44]. Other GABAC receptor antagonists include the bicyclic GABA analog, THIP (Gaboxadol, 4,5,6,7-tetrahydroisoxazolo(5,4-c)pyridin-
3-ol, Figure 2), which is a moderately potent antagonist at the GABAC receptors, yet a potent 
agonist at GABA
A
 receptor receptors [45]. Aza-THIP (1H,4H,5H,6H,7H-pyrazolo[3,4-c]pyri-
din-3-ol) is inactive at GABA
A
 receptors but shows moderately potent antagonism at GABAC receptors. Phosphinic, phosphonic, and seleninic analogs of isonipecotic acid have also been 
shown to act as selective GABAC receptor antagonists [46], as have amide and hydroxamate analogs of 4-aminocyclopent-1-enecarboxylic acid [47].
Unlike many GABA
A
 receptor antagonists, TPMPA is not a convulsant, consistent with many 
instances that GABA
A
 and GABAC receptors have been shown to mediate opposing functions, 
for example, on excitability [48] and in memory formation [49].
TPMPA and other GABAC receptor antagonists have been used to demonstrate the important 
role of GABAC receptors in many aspects of vision [50–53]. TPMPA was shown to inhibit 
Figure 2. GABA
A
 receptor antagonists that are not convulsants.
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form-deprivation myopia [51], while (3-aminopropyl)-n-butylphosphinic acid (CGP36742 or 
SGS742) was found to inhibit the development of myopia in chicks [50]. Thus, TPMPA and 
related GABAC receptor antagonists have been suggested for the treatment of myopia, admin-istered intravitreally, orally, and ophthalmically [52]. Indeed, GABAC receptor antagonists have been patented for the treatment of myopia [52].
GABAC receptor antagonists have also been useful experimental tools for demonstrating 
a role for these receptors in learning and memory [49, 50, 54]. TPMPA and the structural 
analog P4MPA ((piperidin-4-yl)methylphosphinic acid) were shown to enhance short-term 
memory in a bead discrimination task following injection into the multimodal association 
forebrain area in chicks [49]. Injection of bicuculline caused the opposite effect. TPMPA has 
also been used to demonstrate a role for GABAC receptors in fear learning and memory in 
rats [54]. Rats administered TPMPA via bilateral cannulae injections into the lateral amyg-
dala showed reduced freezing in a foot shock conditioned fear task. This reduction in fear 
learning and memory is likely mediated by presynaptically located GABAC receptors in the 
lateral amygdala [54].
Arising out of studies on the orally active GABA(B/C) receptor antagonist (3-aminopropyl)-n-butylphosphinic acid (CGP36742 or SGS742) [55], cis- and trans-(3-aminocyclopentanyl)
butylphosphinic acid were found to be selective potent GABAC receptor antagonists that enhanced learning and memory in rats in the Morris water maze task [50].
Based on the structure of the selective GABAC receptor antagonist (S)-4-ACPBPA [(4-aminocy-clopenten-1-yl)-butylphosphinic acid], a series of fluorescent ligands were produced linking 
fluorophores to the parent compound [56]. One of these fluorescent ligands, (S)-4-ACPBPA-
C5-BODIPY, showed moderately potent antagonism for GABAC receptors with greater than 100 times selectivity for these receptors over GABA
A
 receptors. (S)-4-ACPBPA-C5-BODIPY 
thus provides a valuable molecular probe for the role of GABAC receptors in physiological 
and pathological processes [56].
6. Bilobalide, a nonconvulsant channel blocker
Bilobalide (Figure 2) and a series of terpenoids known as ginkgolides isolated from Ginkgo 
biloba are structurally related to picrotoxinin and are relatively potent GABA
A
 and GABAC 
receptor antagonists [57], but they also act on glycine and 5-HT
3
 receptors [58, 59].
Unlike picrotoxin, bilobalide is an anticonvulsant. This may be due to its potent action on 
GABAC receptors [57]. Bilobalide also has differing effects to those of picrotoxin on the modu-
lation of GABA
A
 receptors by structurally different modulators [60], suggesting a different 
binding profile to picrotoxin to negatively modulate the GABA
A
 receptors.
Thus, there are GABA
A
 receptor antagonists that act as channel blockers and negative modu-
lators that do not produce convulsions in vivo. Explanation of this apparent paradox includes 
selective actions on GABA
A
 receptor subtypes, reduction of glutamate release from presyn-
aptic terminals via presynaptic receptors and effects on GABA metabolism, together with 
actions on non-GABAergic systems.
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Owing to their unique characteristics, bilobalide and other natural terpenoids from Gingko 
biloba are being investigated as cognitive enhancers via their effects on the GABAergic system 
[61]. Bilobalide has been shown to improve cognition in cognitive- and memory-impaired ani-
mals in a variety of animal models [62–65]. As a result to its nonconvulsant effects, bilobalide 
is a superior candidate for therapeutic use in memory impairment related to dementia and 
other neurological disorders compared with other GABA
A
 receptor antagonists like picrotoxin 
which are pro-convulsive. Natural terpenoids from Gingko biloba, such as bilobalide, are being 
investigated in the treatment of neurological disorders via their effects on the GABAergic 
system [61].
The plant-derived triterpenoids, asiatic, oleanolic, and ursolic acids (Figure 2), are negative 
modulators of GABA
A
 receptor activation acting in vivo as anxiolytics, anticonvulsants, and 
antidepressants in animal models [66, 67].
7. S44819, an α5-selective competitive antagonist
The α-β subunit interface has been highlighted as a novel target for subtype-selective drugs [68]. 
An example of a novel drug that targets this binding site and that is attracting considerable cur-
rent attention as a new therapeutic agent is S44819 (Egis-13,529, 8-Methyl-5-[4-(trifluoromethyl)-
1-benzothiophen-2-yl]-1,9-dihydro-2H-[1,3]oxazolo[4,5-h][2,3]benzodiazepin-2-one, Figure 2), 
a novel oxazolo-2,3-benzodiazepine derivative, which selectively inhibits GABA
A
 receptors that 
contain the α5-subunit [69, 70].
S44819 appears to act as a competitive antagonist at the orthosteric site at the α-β subunit inter-
face of GABA
A
 receptors containing only α5 subunits. Thus, S44819 is a competitive antagonist, 
unlike other α5-subunit selective drugs that act as negative allosteric modulators by binding 
to the benzodiazepine recognition site between at the α5-γ2 subunits [71, 72]. Agents that are 
selective for α5 subunit-containing GABA
A
 receptors enhance cognitive performance in a vari-
ety of animal models without sedative or pro-convulsive effects [73]. SR44819 has been shown 
in healthy young humans to be orally active, reaching the cerebral cortex on oral administra-
tion where it increases cortical excitability [74], acting on extrasynaptic receptors to reduce 
tonic inhibition. Consequently, clinical trials are now underway.
8. Other GABA receptor antagonists
It has not been possible to cover all known GABA receptor antagonists in this perspec-
tive. Other important classes of antagonists include sulfated neurosteroids [75] and agents 
derived from 4-PIOL (5-(4-piperidyl)isoxazol-3-ol) [5]. Of particular interest is DPP-4-PIOL 
(4-(3,3-diphenylpropyl)-5-(4-piperidyl)-3-isoxazolol hydrobromide) that selectively antagonizes 
tonic over phasic GABAergic currents in the hippocampus, suggesting a degree of substrate 
specificity [76].
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Salicylidene salicylhydrazide has been reported as a potent antagonist of GABA
A
 receptors 
containing the β1 subunit using a high-throughput screen [77]. It was suggested that salicyli-
dene salicylhydrazide is interacting at a previously unidentified site on the β1 subunit, but 
this does not appear to have been followed up after the initial publication in 2004.
The most potent GABA
A
 receptor antagonist is the convulsant steroid derivative RU5135, 
being some 500 times more potent than bicuculline [78]. It acts as a competitive antagonist, 
sharing a common site of action with bicuculline. However it lacks specificity, as it is also a 
glycine receptor antagonist sharing a common site of action with strychnine [79].
9. Conclusion
There is still widespread interest in GABA receptor antagonists after many years of investiga-
tion. Reflecting on the use of GABA receptor antagonists in the last 10 years, citation counts via 
the Web of Science for publications citing GABA together with a GABA antagonist in the title 
or abstract are as follows: bicuculline 1203, picrotoxin or picrotoxinin 564, gabazine or SR 95531 
290, TPMPA 48, and bilobalide 14. Thus far, there are only four publications directly related to 
the effects of S44819 on cognition.
Nonconvulsant antagonists of ionotropic GABA receptors have considerable therapeutic 
potential in the treatment of cognitive problems, myopia, and other CNS disorders. Such 
antagonists may be useful in the treatment of Down syndrome [62]. The myriad of possible 
subtypes of ionotropic GABA receptors in the CNS as a result of different combinations of 
protein subunits make the search for more subtype-specific agents highly desirable. The high-
throughput analysis of ionotropic GABA receptor subtypes should result in the discovery of 
novel subtype-specific agonists, antagonists, and modulators that have therapeutic potential 
[80]. Clearly, we are going to hear a lot more about S44819 and other yet to be discovered iono-
tropic GABA receptor antagonists that act selectively on ionotropic GABA receptor subtypes.
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